Comparing Alto Neuroscience (ANRO) and Its Rivals

Alto Neuroscience (NYSE:ANRO) is one of 1,075 publicly-traded companies in the “Pharmaceutical preparations” industry, but how does it contrast to its rivals? We will compare Alto Neuroscience to similar companies based on the strength of its profitability, risk, earnings, valuation, dividends, analyst recommendations and institutional ownership.

Volatility and Risk

Alto Neuroscience has a beta of 1.87, meaning that its share price is 87% more volatile than the S&P 500. Comparatively, Alto Neuroscience’s rivals have a beta of 3.80, meaning that their average share price is 280% more volatile than the S&P 500.

Institutional & Insider Ownership

44.0% of shares of all “Pharmaceutical preparations” companies are held by institutional investors. 11.1% of Alto Neuroscience shares are held by company insiders. Comparatively, 13.7% of shares of all “Pharmaceutical preparations” companies are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Alto Neuroscience and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Alto Neuroscience	N/A	-49.28%	-33.52%
Alto Neuroscience Competitors	-3,399.87%	-235.11%	-32.77%

Analyst Ratings

This is a breakdown of recent ratings and price targets for Alto Neuroscience and its rivals, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alto Neuroscience	0	3	4	0	2.57
Alto Neuroscience Competitors	8616	22593	50884	1392	2.54

Alto Neuroscience currently has a consensus target price of $15.40, suggesting a potential upside of 589.04%. As a group, “Pharmaceutical preparations” companies have a potential upside of 226.23%. Given Alto Neuroscience’s stronger consensus rating and higher possible upside, equities analysts clearly believe Alto Neuroscience is more favorable than its rivals.

Earnings & Valuation

This table compares Alto Neuroscience and its rivals top-line revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Alto Neuroscience	N/A	-$36.31 million	-0.88
Alto Neuroscience Competitors	$9.89 billion	$136.15 million	-6.25

Alto Neuroscience’s rivals have higher revenue and earnings than Alto Neuroscience. Alto Neuroscience is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Summary

Alto Neuroscience rivals beat Alto Neuroscience on 8 of the 13 factors compared.

Alto Neuroscience Company Profile

Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder. The company develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties which is in phase 2b clinical trial to treat patients with MDD; ALTO-101, a novel small molecule phosphodiesterase 4 inhibitor which is in phase 1 clinical trial for the treatment of cognitive impairment associated with schizophrenia; ALTO-203, a novel small-molecule histamine H3 receptor inverse agonist which is in phase 1 clinical trial to treat patients with MDD and higher levels of anhedonia; and ALTO-202, an investigational orally bioavailable antagonist of the GluN2B subunit of the NMDA receptor which is in phase 1 clinical trial for the treatment of MDD. In addition, it develops novel pharmacodynamically synergistic combination and biomarker platform that collects patient-specific data to identify biomarker-characterized patient. The company was incorporated in 2019 and is headquartered in Los Altos, California.